Search PubMed⌕ Search

Biomedical subjects

K Kunii

Publications and source records attributed to K Kunii.

45 records · Page 3Linked to original sources
PubMed1982

[The effect of tinidazole on the anaerobic bacterial flora in patients undergoing gynecological surgery].

The various effects have been examined against the anaerobes by administering tinidazole when the operations of gynecology and obstetrics and the following results were obtained. 1. The serum concentrations after the single administration of 1,000 mg of TDZ showed 56.6 micrograms/ml of the peak value (3 hours) and 27.7 micrograms/ml of 24 hours value, and the antibacterial potency was maintained for a long duration. The concentration in the vaginal secretions was 21.8 micrograms/tampon within 24 hours. 2. The detections of anaerobes were made in 74 cases, before the administration, with the results of 1 case alone and 73 cases mixed with aerobes, 10 species and 133 strains being detected, which comprise 33 cases with 1 species, 27 cases with 2 species mixed, 10 cases with 3 species mixed and 4 cases with 4 species mixed. The main species detected were Bacteroides fragilis in 46 strains (34.6%), Peptostreptococcus spp. in 31 strains (23.3%) and Peptococcus spp. in 26 strains (19.5%). 3. The MIC values of the detected bacteria to the TDZ centered upon 0.78 micrograms/ml for Bacteroides fragilis, 3.13 micrograms/ml for Peptococcus spp. and 0.78 micrograms/ml for Peptostreptococcus spp. and those of the others were low, a lot of those being of sensitive strains. 4. The bacteriological effects on the anaerobes were, after the medication, observed to be 71.4% and found significantly more effective than 33.3% of natural eradication and decrease observed in the not administered group. 5. Clinically, no anaerobic infections were observed often operation and the therapeutical effects were observed. A little side effect was observed. 6. According to the above-mentioned results, it was observed possible to prevent from the anaerobic infections after operation in gynecology and obstetrics by administration of TDZ.

Bacteria↗
PubMed1981

[A study of clinical application of cefmetazole in perinatal period (author's transl)].

The fundamental study of cefmetazole treatment in a clinical situation during the perinatal period were made, and the following results were obtained. Absorption of CMZ in pregnant women is rapid; and the intravenous injection intravenous drip infusion and intramuscular injection of CMZ all reached their peak serum levels in a short time with a half-life of approximately 1 hour or so. The transference of CMZ to the fetus through placenta is good. It is so good that a single dose of 0.5 approximately equal to 1.0 g by intravenous injection, intravenous drip infusion or intramuscular injection can obtain desired concentration levels covering MIC of main causative pathogenic organisms in the cord blood, amniotic fluid and blood in the fetus. Therefore, the administration of CMZ with this dose and method of administration once or twice daily can prevent or treat intrauterine infection. The transition of CMZ to mother's milk is a small quantity and the transition of CMZ through mother's milk to a neonate is considered to be a very small amount. The absorption of CMZ in neonate is rapid. It reaches a peak serum concentration 15 minutes after the intravenous injection. The half-life varies depending on the number days after birth. With the administration of 20 mg/Kg, the half-life at 0 day after birth is 6.32 approximately 6.78 hours, 3.79 hours at 1st day after birth and 2.27 approximately 2.72 hours at 5th-6th day after birth. Excretion into the urine is slow on 0 day after birth and becomes rapid on the 6th day after birth, coinciding with the maintained level of CMZ in the blood. Positive results were obtained from the overview of CMZ administration in the prophpylaxis or treatment of intrauterine infection during the perinatal period. No abnormalities were noted from the examinations performed on a neonate delivered from a mother who had received CMZ during perinatal period. Judging from the various results mentioned above, 20 mg/kg of CMZ administered to a neonate twice a day at 12 hour intervals would be sufficient to attain therapeutic efficacy.

Adult↗